Oncothyreon Price Target Cut to $3.00 by Analysts at Wedbush (ONTY)
Analysts at Wedbush cut their price objective on shares of Oncothyreon (NASDAQ:ONTY) to $3.00 in a research report issued to clients and investors on Tuesday. Wedbush’s price target indicates a potential upside of 7.91% from the company’s current price.
Shares of Oncothyreon (NASDAQ:ONTY) opened at 2.78 on Tuesday. Oncothyreon has a 52 week low of $1.67 and a 52 week high of $4.08. The stock’s 50-day moving average is $2.86 and its 200-day moving average is $2.95. The company’s market cap is $196.9 million.
Oncothyreon (NASDAQ:ONTY) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.04. During the same quarter in the prior year, the company posted ($0.28) earnings per share. Analysts expect that Oncothyreon will post $-0.46 EPS for the current fiscal year.
Oncothyreon Inc (NASDAQ:ONTY) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer.
Receive News & Ratings for Oncothyreon Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncothyreon Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.